Abstract: A novel, rapid, simple, stability indicating RP-UPLC method development and validation for simultaneous estimation of methylparaben (MP), mometasone furoate (MF) and eberconazole nitrate (EN) in topical pharmaceutical dosage form. Isocratic chromatographic separation was achieved on Acquity BEH C18, column using mobile phase consist of buffer (0.1%v/v triethylamine in water pH 6.0 by Glacial acetic acid), acetonitrile in the ratio (40:60, v/v) at flow rate 0.4 mL/min and detection was monitored at 235 nm by using photo-diode array detector. The method shows excellent linearity over the range of 2.75-152.7 µg/mL, 4.45-60.7 µg/mL and 9.10-606.6 µg/mL for methylparaben, mometasone furoate and eberconazole nitrate respectively. Recovery was found for all the components to be in the range of 98.4-101.7%. Stability indicating capability of developed method was established by analysing forced degradation samples in which spectral purity of methylparaben, mometasone furoate and eberconazole nitrate along with separation of degradation products from analytes peak. The proposed method was successfully applied for the quantitative estimation of MP, MF and EN in cream sample.
Introduction
Eberconazole nitrate (EN), topical antimycotic agent chemically known as: 1-(2, 4-dichloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1H-imidazole nitrate used topically in the treatment of superficial fungal infections. It is a basic, white, amorphous powder 1, 4 .
Mometasone furoate (MF), topical corticosteroid chemical known as: (11β, 16α)-9, 21-dichloro-11-hydroxy-16-methyl-3, 20-dioxopregna-1, 4-dien-17-yl 2-furoate; has antiinflammatory, anti-pruritic and vasoconstrictive properties. Mometasone reduces the action of allergic reactions, eczema and psoriasis that causes inflammation, redness and swelling.
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Chem Sci Trans., 2014, 3(1), [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] For the treatment of mild to moderate inflammed cutaneous mycoses with antimycotic activity combination of eberconazole nitrate and mometasone furoate used. The preservative system is an important part of semi solid formulations in preventing the deterioration of formulations from microbial contamination. Methylparaben and its salts are the most commonly used preservatives and have been used for many years [5] [6] [7] . A detailed literature survey for methylparaben, mometasone furoate and eberconazole nitrate revealed that determination of individual compound or combination with other drugs have been reported by HPLC [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , LCMS [17] [18] , electrophoresis 19 and spectrophotometric method 20 .
To the best of our knowledge, no RP-UPLC stability indicating method has been reported for the rapid simultaneous determination of MP, MF and EN in combined topical pharmaceutical formulation. Therefore, it is necessary to develop a new rapid and stabilityindicating method for simultaneous estimation of three compounds (MP, MF and EN) in topical pharmaceutical formulation. The proposed method is able to separates MP, MF and EN with each other and from other degradation products. Thereafter, this method was validated according to the ICH guideline 21 and successfully applied for separation and quantification of all compounds of interest in the topical pharmaceutical formulation. Chemical structures of all compounds are presented in Figure 1 . 
Experimental
Drug product, Placebo matrix, working standards were provided by Dr. Reddys Lab, India. HPLC grade acetonitrile, triethylamine and glacial acetic acid were used of Rankem, India. 0.22 µm nylon membrane filter, 0.22 µm PVDF syringe filter and 0.22 µm nylon syringe filter was used of Millipore, India. Water for HPLC was generated using Milli-Q Plus water purification system (Millipore, Milford, MA, USA), analytical grade hydrochloric acid, sodium hydroxide pellets and 30% (v/v) hydrogen peroxide solution were obtained from Rankem, India.
Chromatographic parameters and equipments
All chromatographic experiments were performed on waters acquity UPLC system (Waters, Empower2 software, USA) in the isocratic mode. Separation was achieved on accquity BEH C18 (100×2.1 mm, 1.7 μ) column as stationary phase by using mixture of buffer (buffer=0.1%v/v triethylamine in water pH 6.0 by glacial acetic acid) : acetonitrile (40:60,%v/v) as mobile phase and isocratic mode. Other parameters such as run time 4.0 minutes, 0.4 mL/min as flow rate, injection volume of 1 μL, column temperature of 40 °C were finalized during development. MF, EN and MP was detected at 235 nm. Acetonitrile was used as diluents. The stress degraded samples and the solution stability samples were analyzed using a PDA detector covering the range of 200-400 nm. Photo-stability chamber (Sanyo, Leicestershire, UK) used for photolytic light stressed sample. Dry air oven (Cintex, Mumbai, India). Cintex digital water bath was used for specificity study.
Procedure
Standard solution preparation
The stock solutions of methylparaben (1000 μg/mL), mometasone furoate (400 μg/mL) and eberconazole nitrate (4000 μg/mL) were prepared by dissolving an appropriate amount of standard substances in acetonitrile, separately. Working standard solution was prepared by mixing above stock solutions of methylparaben, mometasone furoate and eberconazole nitrate with final concentration of 100 μg/mL, 40 μg/mL and 400 μg/mL respectively.
Cream sample preparation
An accurately weighed 1 g of sample (equivalent to 20 mg of EN, 2 mg of MF) was taken into 50 mL volumetric flask. About 35 mL of acetonitrile was added to this volumetric flask and sonicated in an ultrasonic bath for 15 min with intermittent shaking, diluted to the volume with acetonitrile, mixed well. Filtered a portion of solution through 0.22 µm nylon syringe filter and the filtrate was collected after discarding first few milliliters.
Placebo (other substances without MP, MF and EN) solution preparation
An accurately weighed 1 g of placebo sample was taken into 50 mL volumetric flask. About 35 mL of acetonitrile was added to this volumetric flask and sonicated in an ultrasonic bath for 15 min with intermittent shaking, diluted to the volume with acetonitrile, mixed well. Filtered a portion of solution through 0.22 µm nylon syringe filter and the filtrate was collected after discarding first few milliliters.
Procedure for method validation
The method was validated for linearity, precision, accuracy solution stability, filter compatibility, limit of detection (LOD), limit of quantification (LOQ), specificity-forced degradation studies and robustness.
System suitability
To ensure that UPLC testing system was suitable for the intended application, the system suitability was assessed by five replicate analysis of system suitability solution and chromatographic parameters were evaluated. The acceptance criteria were not more than 2.0% for the RSD of the peak areas and tailing factor of the analyte peaks. The acceptance criteria were not less than 3000, 5000 and 7500 for the plate count of the MP, MF and EN peak respectively.
Specificity-forced degradation studies
The forced degradation studies were executed to demonstrate whether the analytical method were stability-indicating and could unequivocally assess the analyte in presence of impurities and degradation products. Combined cream of MP, MF and EN were stressed under thermolytic, photolytic, acid hydrolytic, base hydrolytic and oxidative stress conditions to result expect 0-50% partial degradation of the drugs. All stress decomposition studies were performed at an initial drug concentration of 100, 40 and 400 μg/mL for MP, MF and EN respectively.
Acid degradation sample
For acid hydrolysis, solution was prepared by dispersing and dissolving cream sample into 15 mL of acetonitrile. Acid hydrolysis was performed by adding 2 mL of 1N HCl and mixture was kept at room temperature for 30 minutes. Neutralized the solution with 2 mL of 1 N NaOH solution and further procced as per sample preparation.
Base degradation sample
For acid hydrolysis, solution was prepared by dispersing and dissolving cream sample into 15 mL of acetonitrile. Base hydrolysis was performed by adding 1 mL of 0.5 N NaOH and mixture was kept at room temperature for 15 minutes. Neutralized the solution with 1 mL of 0.5 N HCl solution and further procced as per sample preparation.
Peroxide oxidation sample
For oxidation study, solution was prepared by dispersing and dissolving cream sample into 15 mL of acetonitrile. Oxidative study was performed by adding 1 mL of 10% v/v hydrogen peroxide (H 2 O 2 ) and mixture was kept at room temperature for 30 minutes. Further procced as per sample preparation.
Thermal exposed sample
For thermal stress testing, the cream sample was placed in convection oven and exposed to heat at 75 °C for 6 h.
Photolytic light exposed sample
For photo stress testing, the cream sample was placed in photolytic chamber to expose in UV and visisble light (1.2 million lux hours and 200 wh/m 2 ).
Precision
The precision of the developed method was assessed by performing repeatability and intermediate precision (inter-day) at an initial drug concentration of 100, 40 and 400 μg mL -1 for MP, MF and EN respectively, in one day and % RSD was calculated to determine repeatability precision. These studies were also repeated on different days to determine intermediate precision.
Accuracy
To confirm the methods accuracy, recovery experiments were checked by standard addition method. The recovery experiments were performed in triplicate at 50, 100 and 150% concentration levels of the amount of the analytes in in-house mixture of cream excipients (placebo).
Limit of detection and limit of quantification
The limit of detection (LOD) and limit of quantification (LOQ) were defined as the lowest concentration of analyte in a sample that can be detected and quantified. The standard solutions of MP, MF and EN for LOD and LOQ were prepared by diluting them in acetonitrile sequentially. The LOD and LOQ were determined by signal to noise (S/N) ratio for each compound through analyzing a series of diluted solutions until the S/N ratio yield 3 for LOD and 10 for LOQ, respectively.
Linearity
Six levels of calibration standard solutions were prepared from the stock solutions at concentration from 2.75-152.7 µg/mL for MP, 4.45-60.7 µg/mL for MF and 9.10-606.6 µg/mL for EN to encomposed the expected concentration in measured samples. Calibration curves were constructed by plotting areas versus concentrations of MP, MF and EN and then subjected to treat by least-squeres linear regression analysis.
Robustness
To determine the robustness of the method the experimental conditions were deliberately changed. The flow rate of the mobile phase (0.4±0.04 mL/min), column oven temperature (40±5 o C), mobile phase buffer pH (6.0±0.2), varying in acetonitrile composition (60±10%). In each case, the % RSD values were calculated for the obtained peak area. The number of theoretical plates and tailing factors were compared with those obtained under the optimized conditions.
Solution stability
In order to demonstrate the stability of sample solutions, the solution was tested at intervals of 0, 12, 24 h by storage it at ambient temperature for 24 h. The stability of solutions was appreciated by comparing assay results of peak area MP, MF and EN.
Filter compatibility
Filter compatibility was performed for nylon 0.22 µm syringe filter (Millipore) and PVDF 0.22 µm syringe filter (Millipore). To confirm the filter compatibility in proposed method, filtration recovery experiment was carried out by sample filtration technique. Sample was filtered through both syringe filter and percentage assay was determined and compared against centrifuged sample.
Results and Discussion
Method development and optimization
The primary target in developing UPLC method is to achieve simultaneous determination of MP, MF and EN in topical formulations under common chromatographic conditions; those are applicable to routine quality control of products in pharmaceutical and cosmetic industries.
Mobile phase and chromatographic conditions optimization
Column selection and mobile phase selection were done simultaneously. A method development was started with HSS C18 (100×2.1 mm, 1.7 µm) column as stationary phase. mobile phase was buffer (0.1% triethyl amine pH 6.0 with glacial acetic acid) : methanol, 20:80 v/v. Flow rate 0.4 mL/min, column temperature 40 °C. Late elution of EN peak was observed. Further trial was taken by replacing methanol with acetonitrile from mobile phase component and found that the peak shape of EN was not symmetrical (1.5 peak tailing observed). Different mobile phase buffer pH (ranging from 2.5 to 6.5) were employed with phosphate, acetate, perchlorate and formic acid buffers to reduce the peak tailings, but the buffer pH did not play any role in peak tailing for EN. Then trial was taken with different column BEH C18 (100×2.1 mm, 1.7 μm) keeping mobile phase buffer (0.1% triethyl amine pH 6.0 with glacial acetic acid) : Acetonitrile, 20:80 v/v while flow rate was 0.4 mL/min, column temperature 40 °C and found that the peak shape of EN was symmetrical (1.2 peak tailing observed). when base degradation sample was injected into the same chromatographic conditions co-elution of base degradant peak with MF peak was observed. Different organic phase ratio (ranging from 20% to 80%) in mobile phase component employed to separate base degradant peak from MF peak of base degradation sample. From the above experiments, it was observed that to separate base degradant peak from MF peak in base degradation sample organic phase ratio played a role. Good peak shaped for all components with well resolved degradant peaks were observed in all stressed condition samples.
Acetonitrile was used as diluent by considering solubility of all components wavelength was selected by injecting known concentration of each of MP, MF and EN into UPLC with PDA detector and evaluated for UV spectra of each of component. A common wavelength for the simultaneous determination of all components was selected as 235 nm by overlaying spectra and wavelength at which all components have significant absorbance.
Extraction of active components from semisolid sample matrix with acceptable recovery is very critical aspect for sample preparation and was achieved by choose of right diluent in following manner. Considering solubility of all components, Acetonitrile was used as diluent and satisfactory recovery was achieved. Based on the above experimental data, the chromatographic separation was finalized by acquity BEH C18 (100×2.1 mm, 1.7 μm), column using isocratic elution at 235 nm detection wavelength. The optimized mobile phase consist of buffer (0.1%v/v triethylamine in water pH 6.0 by glacial acetic acid), acetonitrile in the ratio (40 : 60 v/v), respectively within 4.0 minutes run time, while mobile phase flow rate at 0.4 mL/min, 40 °C (column oven) temperature with 1 μL Injection volume. By using above chromatographic condition and diluent; standard, sample and placebo preparation were prepared and injected into UPLC with developed parameters (Figure 2 ).
Figure 2. Typical overlay chromatogram of blank and placebo and standard preparation
Analytical method validation
After satisfactory development of method it was subjected to method validation as per ICH guideline 22 .
System suitability
System suitability parameters were measured so as to verify the system, method and column performance. 
Specificity-forced degradation studies
Specificity is the ability of the method to measure the analyte response in the presence of its potential impurities and placebo matrix 22 . Forced degradation studies were performed to demonstrate selectivity and stability indicating capability of the proposed RP-UPLC method. Figure 2 shows that there is no any interferences at the RT (retention time) of MP, MF and EN due to blank, placebo. Overlay chromatograms of blank, placebo and standard are presented in Figure 2 .
Force degradation studies of drug product were also performed to evaluate the stability indicating property and specificity of proposed method. The solutions of drug product and placebo were exposed to acid hydrolysis study (2 mL of 1 N HCl at RT for 30 min), alkali (0.5 mL of 0.5 N NaOH at RT for 15 min), peroxide oxidation (1 mL of 10%v/v H 2 O 2 at RT for 30 min), thermally exposed (75 °C, 6 h) and photolytic exposed (drug product exposed to visible light for 240 h resulting an overall illustration 1.2 million lux hours and UV light for 250 h resulting an overall illustration 200 w h/m 2 at 25 °C). MF was found sensitive to acid hydrolysis than EN. During acid hydrolysis process, about 18.0% of MF was degraded and one main degradation peak was observed at 2.127 min, 8.6% of MP was degraded while no degradation was observed in case of EN. MF was found sensitive to base hydrolysis than EN. During base hydrolysis process, about 20.8% of MF was degraded and one main degradation peak was observed at 2.066 min while 5.4% of MP was degraded and no obvious degradation peak was observed, no degradation was observed in case of EN. During photolytic light exposed degradation process, about 37.6% of MF was degraded and two main degradation peak was observed at 1.288 min, 1.495 min, while no degradation was observed in case of EN and MP. No degradation observed for thermally exposed sample (75 °C, 6 h) and peroxide oxidation sample (1 mL of 10%v/v H 2 O 2 at RT for 30 min). Acid hydrolysis sample, base hydrolysis, peroxide oxidation sample, thermal exposed sample and photolytic light exposed sample are presented in Figure 3(a), 3(b), 3(c), 3(d) and 3(e) , respectively. Peak due to MP, MF and EN were investigated for spectral purity in the chromatogram of all exposed samples and found spectrally pure. The purity and assay of MP, MF and EN were unaffected by the presence of its degradation products and thus confirms the stability-indicating power of the developed method. Results from forced degradation study are given in Table 2 . 
Method precision (Repeatability)
The precision of assay method was evaluated by carrying out six independent determinations of of MP, MF and EN (100 μg mL -1 of MP, 40 μg mL -1 of MF and 400 μg mL -1 of EN) cream samples against qualified working standards. The average % assay (n=6) of MP, MF and EN were 99.8%, 100.3% and 101.6% respectively with RSD of below 1.0%. Low values of % RSD, indicates that the method is precise. Results are presented in Table 3 .
Intermediate precision (Reproducibility)
The purpose of this study is to demonstrate the reliability of the test results with variations. The reproducibility was checked by analyzing the samples by different analyst using different chromatographic system and column on different day. Results are presented in Table 3 .
Accuracy
The accuracy was evaluted applying the proposed method to the analysis of the in house mixture of cream excipients with known amount of the drug, to obtain solutions at concentrations of 201.0, 402.0 and 603.0 μg/mL repectively for MP; 20.1, 40.2 and 60.3 μg/mL repectively for MF; 50.6, 101.2 and 151.8 μg/mL repectively for EN. The accuray was assessed from three replicate determination and calculated as the μg/mL drug recovered from the drug matrix. The means and RSD% obtained from the recovery study are shown in Table 4 with a range of 99.0-101.7%, 99.8-101.1% and 98.5-101.5% for MP, MF and EN, respectively, demonstrating that the method is accurate with in the desired range and also there is no interference due to excipients present in placebo cream sample.
Limit of detection (LOD) and quantification (LOQ)
The LOD and LOQ were determined at a signal-to-noise ratio of 3:1 and 10:1, respectively, by injecting a series of dilute solutions with known concentrations. The limit of detection and limit of quantification values of MP, MF and EN are reported in Table 3 . 
Linearity
Linearity was demonstrated of standard concentration using minimum six calibration levels of test concentration in the range of 2.75-152.7 µg/mL for MP, 4.45-60.7 µg/mL for MF and 9.10-606.6 µg/mL for EN, which gave us a good confidence on analytical method with respect to linear range. The response was found linear for all MF, EN and MP from LOQ to 150% of standard concentration and correlation coefficient was also found greater than 0.999. Bias was also found within ±0.80. The result of Correlation coefficients, y-intercept of the calibration curve and % bias at 100% response for MP, MF and EN are presented in Table 3 . 
Robustness
The robustness as a measure of method capacity to remain unaffected by small, but deliberate changes in chromatographic conditions was studies by testing influence of small changes in flow rate (0.4±0.04 mL/min), varying in column oven temperature (40±5 °C), varying mobile phase buffer pH (6.0±0.2), varying in mobile phase acetonitrile composition (60±10%). At deliberate varied chromatographic conditions (flow rate, column oven temperature, mobile phase buffer pH, mobile phase acetonitrile composition), %RSD of MF, EN and MP were calculated from peak area count of five replicate injections. Tailing factor and theoretical plate count remain closer to actual values. Thus, the method was found to be robust with respect to variability in above conditions. The results are presented in Table 1 along with system suitability parameters of precision and intermediate precision study.
Stability of sample solution
Stability of sample solution was established by storage it at ambient temperature for 24 h. The assay of MP, MF and EN were analyzed. It was found that % labeled amount of MP at 0, 12 and 24 h were 99.8, 100.2 and 100.8, respectively; % labeled amount of MF were 100.3, 99.6 and 99.8, respectively and % labeled amount of EN were 101.6, 101.7 and 102.1, respectively.
Filter compatibility
Sample solution was not showing any significant changes in assay percentage with respect to centrifuged sample. It was found that % labeled amount of MP at centrifuged sample, 0.22 µm PVDF syringe filter and 0.22 µm nylon syringe filter were 100.2, 100.2 and 100.5, respectively; MF were 100.5, 100.8 and 99.9, respectively and EN were 101.2, 100.9 and 100.8. In obtained result difference in %assay was not observed more than ±1.0, which indicates that both syringe filters having a good compatibility with sample solution.
Conclusion
A rapid isocratic RP-UPLC method was successfully developed for the simultaneous estimation of methylparaben, mometasone furoate and eberconazole nitrate in combined topical pharmaceutical dosage form. The method validation results have proved that the method is selective, precise, accurate, linear, robust, filter compatible and stability indicating. Forced degradation data proved that the method is specific for the analytes and free from the interference of placebo / known impurities / and degradation products. The run time (4.0 min) enables for rapid determination of drug. Moreover, it may be applied for individual and simultaneous determination of methylparaben, mometasone furoate and eberconazole nitrate in the study of content uniformity, tube homogeneity and in vitro release test profiling of mometasone furoate and eberconazole nitrate combined topical pharmaceutical dosage forms, where sample load is higher and high throughput is essential for faster delivery of results. The developed method is stability-indicating and can be used for quantifying methylparaben, mometasone furoate and eberconazole nitrate in topical pharmaceutical dosage forms and their combinations (i.e. MP+MF; MP+EN, MF+EN and MP+MF+EN).
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